Tarsus Pharmaceuticals Inc
Change company Symbol lookup
Select an option...
TARS Tarsus Pharmaceuticals Inc
GOVT iShares U.S. Treasury Bond ETF
BAC Bank of America Corp
$NQASPA50JPYN Nasdaq ASPA Industrials Net Total Re
SNP China Petroleum & Chemical Corp
GAEC Gulf Alternative Energy Corp
RDBX Redbox Entertainment Inc
AFG American Financial Group Inc
MRNA Moderna Inc
PFE Pfizer Inc
Go

Health Care : Pharmaceuticals |
Company profile

Tarsus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapeutic candidates to address ophthalmic conditions. Its lead product candidate, TP-03, is a therapeutic being developed for the treatment of blepharitis caused by the infestation of Demodex mites (Demodex blepharitis). TP-03 is a therapeutic based on the drug, lotilaner, which is designed to paralyze and eradicate mites and other parasites through the inhibition of parasite-specific gamma-aminobutyric acid-gated chloride (GABA-Cl) channels. The Company is also developing additional clinical-stage product candidates with lotilaner. These include TP-04 for the treatment of rosacea as well as TP-05 for Lyme prophylaxis and community malaria reduction.

Closing Price
$25.00
Day's Change
-2.70 (-9.75%)
Bid
--
Ask
--
B/A Size
--
Day's High
27.48
Day's Low
25.00
Volume
(Average)
Volume:
41,633

10-day average volume:
46,038
41,633

Netflix's new 'ho-hum' dynamic wins praise

12:00 pm ET October 20, 2021 (MarketWatch)
Print

By Emily Bary

Investors may have been expecting a rosier outlook given the popularity of 'Squid Game,' but some say the company's more muted view is for the best

By the standards of Netflix's usual post-earnings swings, Wednesday's stock-price decline of less than 1% seems pretty mild in comparison.

But this more muted dynamic could be for the best, according to some analysts.

"For a stock that's up 20% since 2Q earnings...we think ho-hum may actually be healthier over time," wrote J.P. Morgan's Doug Anmuth following Netflix's third-quarter report that came out late Tuesday.

While investors might have felt that they "didn't learn much from the quarter" or that they expected Netflix to offer a more encouraging forecast based on the viral success of "Squid Game," Anmuth likes that the company seems to have more visibility into its business.

He raised his price target on the stock to $750 from $705, while reiterating an outperform rating.

The stock (NFLX) slipped 0.9% in midday trading. The stock has suffered a one-day post-earnings decline after nine of the previous 12 quarterly reports, with an average decline of 4.3%.

See more: Netflix earnings, subscribers get a 'Squid Game' bounce, but forecast is tamer

Morgan Stanley's Benjamin Swinburne took a similar view, even though the company's results and outlook were "as 'in-line' as it gets for Netflix," in his view.

"[T]hat does not diminish the importance of validating the move in shares and future growth potential," he wrote, given the heavy enthusiasm heading into the report.

Now that Netflix's subscriber growth looks more "dependable" and less reliant on COVID-related factors, its stock could hold appeal with investors focused on growth and with growth at a reasonable price (GARP) mindsets, as they could be warming to the company's 'utility-like' nature," wrote Wells Fargo's Steven Cahall, who kept his overweight rating on the stock and raised his price target to $800 from $700.

With Netflix shares trading at about 46 times 2023 earnings estimates, they're "hardly inexpensive," but Cahall thinks they're worth a premium price given the company's "consistency of performance to deliver hits, drive subs/revenues and grow earnings." He urges investors to focus less on valuation and more on the "quality and sustainability of growth."

Evercore ISI analyst Mark Mahaney acknowledged that investors might be disappointed that Netflix didn't come in ahead of expectations with its outlook, but he's still optimistic about the current quarter and beyond.

"[W]e would note that Q4 is typically one of Netflix's seasonally strongest quarters and the one quarter of the year where the company has consistently up-sided its net adds guidance -- every year since 2016," he wrote. "Given the very robust strength of the Q4 content slate and the tailwind created by Squid, we suspect that NFLX will continue this steak in 2021, further boosting share price performance."

Mahaney has an outperform rating on Netflix's stock and upped his price target to $710 from $695.

Opinion: As Netflix growth slows, streaming pioneer plans to open up its viewer metrics

Other analysts took less upbeat views, including Deutsche Bank's Bryan Kraft, who downgraded the stock to hold from buy. "While, on the one hand, we share the market's enthusiasm toward Netflix's very strong 4Q content slate and the optionality it brings to 4Q net adds; on the other hand, we think a 4Q subscriber beat is already more than priced into the stock," he wrote.

MoffettNathanson's Michael Nathanson highlighted how Netflix seems to be having success by taking a different content strategy than its peers. While others are being strategic about trying to build hits, Netflix is spending heavily and its "success feels more like a random walk where 'hits' are first discovered by their users, then amplified by the marketing engine that is Netflix's user interface and algorithms," he wrote.

That's certainly a "moat," in his view, but one that is less deep than those of tech titans like Amazon.com Inc. (AMZN), Apple Inc. (AAPL), and Alphabet Inc.'s (GOOGL)(GOOGL) Google. As such, Nathanson has "remained staunchly unwilling to pay for the market's long-term valuation of Netflix's perceived high barriers to entry." He argued that, rather than pay roughly 24 times 2025 earnings estimates for Netflix's stock, investors could pay 18 times to 23 times 2022 earnings estimates for Facebook Inc. (FB) or Alphabet shares.

Nathanson has a neutral rating on the stock and slightly increased his price target to $470 from $465. "We would not be surprised to see the stock sell off when the realization of minimal earnings revisions gets fully processed," he wrote.

Shares of Netflix are up 19% over the past three months as the S&P 500 index has risen about 5%.

-Emily Bary

	

(END) Dow Jones Newswires

October 20, 2021 12:00 ET (16:00 GMT)

Copyright (c) 2021 Dow Jones & Company, Inc.

Earnings Calendar and Events Data provided by |Terms of Use| © 2021 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2021. All rights reserved.